Patents by Inventor Donald O'Boyle

Donald O'Boyle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Puzzle assembly
    Publication number: 20070205555
    Abstract: A display puzzle and method for marketing a product using the display puzzle is provided and includes selecting at least one graphic image, dividing the at least one graphic image into a plurality of image portions, disposing at least one of the plurality of image portions on at least one surface of a container and arranging a plurality of the surfaces in a predetermined arrangement to form the at least one graphic image.
    Type: Application
    Filed: February 14, 2006
    Publication date: September 6, 2007
    Inventors: Donald O'Boyle, Andrea O'Boyle
  • Iminothiazolidinones as inhibitors of HCV replication
    Patent number: 7183302
    Abstract: Compounds having the structure of formula I are described wherein R, R?, R1, R2, and R3 are as defined in the specification. The compounds can inhibit hepatitis C virus (HCV) replication, and in particular the function of the HCV NS5A protein.
    Type: Grant
    Filed: August 8, 2003
    Date of Patent: February 27, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jeffrey Lee Romine, Scott W. Martin, Lawrence B. Snyder, Michael Serrano-Wu, Milind Deshpande, Darren Whitehouse, Julie Lemm, Donald O'Boyle, Min Gao, Richard Colonno
  • Inhibitors of HCV replication
    Publication number: 20060276511
    Abstract: Compounds having the structure of formula I are described. The compounds can inhibit hepatitis C virus (HCV) replication, and in particular can inhibit the function of the HCV NS5A protein.
    Type: Application
    Filed: June 5, 2006
    Publication date: December 7, 2006
    Inventors: Michael Serrano-Wu, Makonen Belema, Lawrence Snyder, Nicholas Meanwell, Denis St. Laurent, Ramesh Kakarla, Van Nguyen, Yuping Qiu, Xuejie Yang, John Leet, Min Gao, Donald O'Boyle, Julie Lemm, Fukang Yang
  • Hepatitis C virus assays
    Publication number: 20050260568
    Abstract: The present invention includes assays useful for identifying inhibitors of Hepatitis C virus (HCV) activity. Particularly, the present invention is directed to a HCV assay useful for high throughput screening that quantifies both the amount of HCV RNA replication inhibitory activity associated with a test compound and the amount of cytotoxicity associated with that test compound, as well as the specificity of that compound for HCV over closely-related viruses (such as Bovine viral diarrhea virus). The present invention also includes compounds discovered using this assay, compositions containing such compounds and methods of treating Hepatitis C by the administration of such compounds.
    Type: Application
    Filed: April 29, 2005
    Publication date: November 24, 2005
    Inventors: Min Gao, Julie Lemm, Donald O'Boyle, Peter Nower
  • Iminothiazolidinones as inhibitors of HCV replication
    Publication number: 20050096364
    Abstract: Compounds having the structure of formula I are described wherein R, R?, R1, R2, and R3 are as defined in the specification. The compounds can inhibit hepatitis C virus (HCV) replication, and in particular the function of the HCV NS5A protein.
    Type: Application
    Filed: August 8, 2003
    Publication date: May 5, 2005
    Inventors: Jeffrey Romine, Scott Martin, Lawrence Snyder, Michael Serrano-Wu, Milind Deshpande, Darren Whitehouse, Julie Lemm, Donald O'Boyle, Min Gao, Richard Colonno
  • Combination pharmaceutical agents as inhibitors of HCV replication
    Publication number: 20050069522
    Abstract: Disclosed are combination pharmaceutical agents for the treatment of an HCV infection comprising a compound effective to inhibit the function of the HCV NS5A protein and another compound having anti-HCV activity. Compounds which can inhibit the function of the NS5A protein having the structure of formula I are described wherein R, R?, R1, R2, and R3 are as defined in the specification. The other compounds having anti-HCV activity are effective to inhibit the function of a target selected from the group consisting of HCV metalloprotease, HCV serine protease, HCV polymerase, HCV helicase, HCV NS4B protein, HCV entry, HCV assembly, HCV egress, HCV NS5A protein, IMPDH and a nucleoside analog for the treatment of an HCV infection.
    Type: Application
    Filed: August 8, 2003
    Publication date: March 31, 2005
    Inventors: Richard Colonno, Julie Lemm, Donald O'Boyle, Min Gao, Jeffrey Romine, Scott Martin, Lawrence Snyder, Michael Serrano-Wu, Milind Deshpande, Darren Whitehouse